Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]

Affiliations

¹ Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
² Poznan University of Medical Sciences, Poland.
³ Wroclaw Medical University, Poland.
⁴ Instituto Hispalense de Pediatría, Sevilla, Spain.
⁵ Clinical Research Center, Tartu, Estonia.
⁶ The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel.
⁷ Telethon Kids Institute and School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia.
⁸ Merck & Co., Inc., Rahway, NJ, USA.
⁹ Merck Canada Inc., Kirkland, QC, Canada.
¹⁰ MSD B.V., OSS, the Netherlands.
¹¹ Merck & Co., Inc., Rahway, NJ, USA. Electronic address: natalie.banniettis@merck.com.
¹² MSD (UK) Limited, London, United Kingdom.

Free article

Published Erratum

Federico Martinon-Torres et al. Vaccine. 2025.

Free article

. 2025 Feb 27:48:126628.

doi: 10.1016/j.vaccine.2024.126628. Epub 2025 Jan 20.

¹ Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
² Poznan University of Medical Sciences, Poland.
³ Wroclaw Medical University, Poland.
⁴ Instituto Hispalense de Pediatría, Sevilla, Spain.
⁵ Clinical Research Center, Tartu, Estonia.
⁶ The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel.
⁷ Telethon Kids Institute and School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia.
⁸ Merck & Co., Inc., Rahway, NJ, USA.
⁹ Merck Canada Inc., Kirkland, QC, Canada.
¹⁰ MSD B.V., OSS, the Netherlands.
¹¹ Merck & Co., Inc., Rahway, NJ, USA. Electronic address: natalie.banniettis@merck.com.
¹² MSD (UK) Limited, London, United Kingdom.

No abstract available

Erratum for

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Martinon-Torres F, Wysocki J, Szenborn L, Carmona-Martinez A, Poder A, Dagan R, Richmond P, Gilbert C, Trudel MC, Flores S, Lupinacci R, McFetridge R, Wiedmann RT, Chen Q, Gerrits H, Banniettis N, Musey L, Bickham K, Kaminski J; V114-025 PNEU-PED-EU-1 study group. Martinon-Torres F, et al. Vaccine. 2023 May 16;41(21):3387-3398. doi: 10.1016/j.vaccine.2023.04.036. Epub 2023 Apr 25. Vaccine. 2023. PMID: 37105892 Clinical Trial.